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reader is familiar with the standard equation for O 2 -carrying capacity (Table 1) . It is often shortened by dropping the dissolved O 2 portion (0.0031 ϫ arterial O 2 saturation) as being inconsequential to the total O 2 content. That assumption is misleading. In some circumstances, such as moderate-to-severe anemia, dissolved O 2 becomes more important. Dissolved O 2 not only is important in hyperbaric medicine, but is basic to all tissue aerobic activity. It is from dissolved O 2 that tissues derive their metabolic O 2 (3, 26, 30, 32, 53) . Erythrocytes travel through the plasma surrounded with dissolved O 2 varying in partial pressure, depending on the distance from the red cell membrane (32) . A few nanometers in all directions from the erythrocyte surface plasma dissolved O 2 content drops (32) . Gas partial pressures are dramatically different in various compartments and lowest in tissues ( Table 2 ). Erythrocytes stream in the center of vessels in laminar flow, and, even in capillaries, their concentration is tightly held between 12 and 15%. In turbulent flow conditions, erythrocytes will tumble and mix, but it is still clear that some amount of plasma exists between erythrocytes and endothelial surfaces. The glycocalyx is essentially water based and intercedes between the red cell, its high surrounding O 2 partial pressure, and the endothelium. The aqueous-based media, plasma, therefore forms an insulator (plasma gap) barrier for the movement of O 2 from Hb to tissues. The movement of O 2 from Hb to the mitochondria of a distant cell has been expressed in an equation (Table 1) and ultimately limits the viable distance of tissue cells from capillaries (31) . Endothelial cells, constantly exposed to blood flow, are exquisitely sensitive to O 2 flux. The major resistance to O 2 diffusion lies between Hb and the target mitochondria in tissues (17) . It is this author's contention that the presence of PFC micelles in close proximity to each other as well as their proximity to the erythrocyte shortens diffusion distance that O 2 would have to cross plasma (resistor). The result of shortened distance and reduced resistance is an enhanced tissue O 2 availability.
Gases are carried in PFC by increased solubility (compared with water-based fluids). Liquid gas solubility is governed by Henry's Law: At a constant temperature, the amount of gas dissolved in a given type (plasma or PFC) and volume of liquid is directly proportional to the partial pressure of that gas in equilibrium with that liquid. Every fluid has an inherent solubility coefficient for each gas based on relative molecular polarity (and size). O 2 solubility in plasma is low (0.0031 ϫ arterial PO 2 ) at sea level. Hb establishes an O 2 "bank" that pressurizes the surrounding plasma with O 2 (3, 26, 30 -32, 53, 74) . The solubility of gases in some PFCs are listed in Tables 2 and 3 . Pure PFC is immiscible with water and cannot be injected intravenously, but can be used medically in other ways (not covered in this article) (25, 33, 58, 73, 77) . Lipid micelle encapsulations of PFCs result in small particle sizes (ϳ0.2 m). Presently, the emulsion particles range from 1/10 to 1/100th the size of an erythrocyte (depending on whether you measure volume or circumference). Their relative surface-to-volume ratio is larger and more favorable for gas exchange than that of erythrocytes. Small particle size means that the PFC particles are marginated along the endothelial border. That may well have importance in cell preservation and in NO movement. The O 2 content equation can be rewritten based on the solubility of O 2 in PFC (Table 1) . This equation emphasizes PFC as a third compartment for IV gas-carrying capacity. Researchers have stressed that, to get the maximum O 2 delivery from IV PFC, it is necessary to increase the partial pressure of inhaled O 2 to its maximum (560 Torr) (55, 24) . The limitation of lung transfer of O 2 was a short fall for using the PFCs in some researchers' minds. A trauma victim, for example, who might benefit from a PFC, could have lung damage and be unable to fully utilize the O 2 -carrying capacity of an IV load of PFC, if thirdcompartment loading were the only advantage of IV PFC. The third-compartment capability of PFC is potentially unobtainable in most patients, whereas enhanced gas to tissue delivery due to decreased gas flow resistance happens with all PFC administration.
The small particle size of PFC micelles closes the plasma gap, filling it with microparticles ( Fig. 1 ). Therefore what previously had been an impediment to gas delivery (plasma gap) becomes a conduit (with PFC) for O 2 (and other gases) 
Y, relative saturation of Hb; O2max, maximum O2 carrying capacity of Hb (100% saturation) (in ml O2/100 ml blood) and equals 0.45 ϫ %hematocrit; VRBC, fractional volume of the red blood cell; Vplasma, fractional volume of the plasma; P, total ambient pressure. When a 1 g ⅐ PFC Ϫ1 ⅐ kg dose Ϫ1 is added to the blood of a 4-kg cat, it is 0.7 ml O2. This represents a 30% increase in total oxygen in the blood, but it is all present and available for metabolism, since it is dependent only on Henry's law for dissociation. IV. Gradient of O2 from an erythrocyte (Hb) to the mitochondria (17) This biocomputational modeling uses previously observed parameters of particle size behavior and assumes that all capillaries are homogeneous. In that respect, the model is incomplete/oversimplified, as we know that capillary density, flow gas movements between vessels, arterials, venules, and capillaries do vary. Furthermore, the vessel walls are assumed to be of a finite thickness, and the myoglobin consumes O 2 at a stable rate. Again, this is not the real state over time and between tissues. Also, this model assumes that convection of red cells is negligible, and, therefore, it only computes the effects of PFC and plasma on delivery of gas (17) . The most important concept to grasp from this modeling is the mass transfer coefficient cap , which has a reference value of 6.3 ϫ 10 Ϫ12 ml O 2 ⅐s Ϫ1 ⅐Torr Ϫ1 . With PFC added to the models, the intracapillary mass transfer coefficient increases by 14% and 9% to whole muscle if the hematocrit is 25%. With a 43% hematocrit, the relative increase in capillary mass transfer is only slightly increased, but, because of the extra O 2 available to the PFC, the total O 2 delivered is much more (17) . The entirety of the modeling is complex, and the reader is encouraged to examine the full article, including extensive equations, for how O 2 flows through the various resistances (17) . Even with this modeling, the mass movement of O 2 does not come up to the 10-to 50-fold increase in solubility mentioned above.
PFC is most effective, not as a third compartment of gas storage, but as a "supercharger" of O 2 delivery. O 2 delivery with PFC is best when hematocrit is normal rather than with anemia (17, 31) . It is through a complete understanding of gas flux within tissues to and from PFC that we can use them. Work is just beginning to experiment with the consequences if all respiratory gases (O 2 , CO 2 , NO, N 2 , etc.) were 10 -50 times more soluble (diffusible) in plasma than previously possible.
One paper has examined NO movement with and without PFC. It appears that, when PFC is present, NO moves away from endothelial cells and smooth muscle at a faster rate. It is this author's hypothesis that enhanced gas movement, already demonstrated with the O 2 flow from Hb to target tissues in the presence of PFCs, may enhance NO movement from endothelial cells to Hb in erythrocytes streaming through the center of blood vessels. Such a hypothesis is not yet proven, but fits with the biocomputational modeling. Table 4 lists the solubility of various gases in a PFC presently undergoing testing. Future work will need to focus on the movement of not only O 2 , but also N 2 , CO 2 , and NO. Enhanced O 2 delivery to tissues with reduced blood flow is possible with PFC. An isolated rabbit (Langendorf) heart preparation slowed coronary flow 100-fold. The heart continued to beat, but only with added PFC (70) . If even a trickle of plasma moves (convectively), PFC particles are carried along. Convective O 2 flow (mass forward motion of erythrocytes/PFC particles) is less important than diffusive movement along a partial pressure gradient (17, 25, 31-33, 50, 58, 73, 77) . A number of animal ischemia models (brain, heart, and kidney) have been performed with PFCs (1, 4 -7, 10, 12, 13, 27-29, 35-40, 45, 51, 52, 57, 65, 68, 69, 71, 76). Significant reductions in infarction (cerebral, myocardial) size are reported. Fluosol-DA-20% gained FDA approval by prevention of coronary ischemia. Its efficacy was due to the effects of Henry's Law (in PFCs), enhanced O 2 delivery, and small particle size. Future study should examine PFCs as adjuvant treatments to "supercharge" delivery of O 2 . Animal experiments with added IV PFCs during cardiopulmonary resuscitation, treatment of sickle cell crisis, spinal cord injury, stroke, and myocardial infarction/preservation are underway. Early human trials for traumatic brain injury (TBI), a microcirculation O 2 deficit problem, have been conducted, and large human trials are proposed. Organ preservation for heart surgery, cardioplegia, and for transplantation (heart and kidney) have been and are now being studied. All of these future applications of PFCs will be based on enhanced O 2 delivery. NITROGEN N 2 insolubility in plasma is quite similar to O 2 . Tissue is 70% water, and N 2 is insoluble in tissues. Humans live in a very narrow partial pressure environment on the Earth's surface. The atmosphere is a fluid exerting partial pressure on all of our tissues equally. Humans can adapt to higher altitudes and depths, but sudden movements between them cause physiological problems. All of our tissues (aqueous media) are saturated with N 2 (as well as O 2 ) in equilibrium with the barometric pressure at which we have been breathing. Sudden loss of pressure will result in super saturation of the tissues and plasma, such that bubbles form. Undersea, the body reequilibrates to the surrounding ambient pressure. If breathing air, N 2 is driven into tissues based on each tissue's relative blood flow and N 2 compartment solubility. On surfacing, N 2 exits at a differential speed of tissue equilibration. Henry's Law governs the gas movement based on blood flow, partial pressure gradients, as well as each tissue N 2 solubility. The fast compartments (brain, muscle, organs, etc.) equilibrate quickly, whereas integument, fat, and bone take far longer to reach saturation or equilibrium (43) . The slow compartments continue to on-gas from fast compartments until all tissues equilibrate. Therefore, the fast compartments serve as the depot by which N 2 is added to and subtracted from the body ( Table 1) .
As a diver rises in a water column, N 2 partial pressure is decreased in the lungs and fast compartments. The relative partial pressure in that fast compartment might well still be higher than in the slow compartments that have not yet equilibrated. Fat and integument continue to on-gas N 2 , even if the total body is off-gassing N 2 . That fact can be confusing. An equation can be written for movement of N 2 (or any other gas) ( Table 1 ). Blood/tissue gas solubility changes as soon as PFC is added to blood/tissue.
First-generation PFCs (Fluosol-DA-20% and FC-43) were tested in small animals (hamsters and rats) with acute, severe bounce dive (6 -7 ATA for 30 -60 min) profiles (66, 65) . These bounce dives saturated the fast compartments with N 2 . If N 2 is 10 -50 times more soluble in PFC than plasma, it is intuitive that IV PFC should be a simple "prevention or cure" for the bends. Early experiments showed a 65% decrease in mortality (65, 66) . In a rabbit venous gas embolism (VGE) lethality study, the use of FC-43 and 100% O 2 dramatically increased survival time (67) . In coronary and carotid artery arterial gas embolism (AGE), FC-43 reduced cerebral infarction and increased speed of myocardial recovery (65, 67) . Air embolism is a significant problem in neurological, orthopedic, gynecological, and cardiac surgery. In cardiac surgery, the cardiopulmonary bypass (CPB) machine creates microbubbles. These microbubbles can cause neuropsychiatric changes (40 -80% of all heart surgery patients). A swine CPB model tested PFC and massive carotid air embolism. Animals were randomized to receive either sham (saline) or air (5 ml/kg up to 150 ml) embolism and control (6% hetastarch) or PFC (Oxyflur HemaGen, St. Louis, MO) added to the CPB reservoir (10). All animals had 100% O 2 swept through membrane oxygenators CPB. Oxyflur was undergoing phase II FDA testing during the 1990s. Animals in the control CPB prime group (no PFC) that received an air embolism demonstrated a loss of cerebral blood flow, flattening of their electroencephalogram, and multiple cerebral infarctions at necropsy (10) . The swine that received PFC had an increase in cerebral blood flow, only partial loss of EEG signal with recovery, and no cerebral infarctions. Collaborating work from London demonstrated that, by adding the same PFC to the reservoir of a bubble oxygenator CPB ma- chine in an anesthetized dog model, retinal (a surrogate for cerebral) air emboli could be reduced up to 98% (2) .
In an attempt to further decompression sickness (DCS) treatment, a novel experiment was undertaken examining tissue off-gassing with added PFC. Dogs were allowed to breathe xenon to the point of tissue saturation (47) . With PFC, the removal of xenon from muscle was increased 33%. PFC did increase inert-gas flux, but not by the 30-to 50-fold expected from enhanced solubility alone. A large animal (swine) survival study was undertaken at the United States Navy (NMRC) Dive Physiology Laboratories in Bethesda, MD (14) . This study was made to mimic a worst case scenario of disabled submarine (DISSUB) escape. Such a DISSUB disaster could lead to over 150 sailors with various stages and severity of DCS (potentially 2-4 ATA). Movement/coordination of recompression chambers, supplies, medical support, and trained personnel to a remote location would be, at best, a logistical nightmare. Therefore, a simple, surface pharmaceutical treatment either delaying or obviating the need for recompression has long been sought. In the breakthrough swine study, animals were compressed to 4.8 ATA, breathing air for 22 h (tissue saturation). Immediately at the surface, animals received one of three treatments: control (no treatment), 95% O 2 therapy (in a Plexiglas box), or O 2 therapy plus IV PFC. The PFC was administered IV within 10 min of surface (14) . Mortality was statistically reduced only in the animals that received PFC. No animals that received PFC exhibited any neurological (a fast equilibrating tissue) DCS, whereas seizures and paralysis were common in the groups not receiving PFC (44) .
If PFC at surface works, then a follow-on corollary would be to administer the PFC before decompression (11, 44) . From these studies, it was shown that treatment with PFC at depth was not as effective as PFC administered at surface (Fig. 3) (11, 79). Some animals had a short period of O 2 prebreathing (N 2 off-gassing) before rising to the surface. PFC increases tissue O 2 delivery, as well as removes N 2 . If victims have PFC administered, and they undergo either recompression or primary escape from depth, it is possible that cerebral O 2 toxicity (seizures) might result (11, 79) . Research has demonstrated that there is a small, measurable, increased risk of seizure with PFC circulating intravenously when animals are compressed (11, 79) . Could the dive profile for recompression after DCS be somehow altered if PFC had already been administered? That might well be a possibility, but, even more important than the length of time, stops and depth of recompression might well be the composition of inhaled gas (O 2 prebreathing) for either divers (DISSUB victims) on primary ascent or at medical treatment (recompression).
From the earliest work with DCS, VGE, and AGE, PFC was a promising pharmaceutical treatment for gas embolism/DCS because of the enhanced N 2 solubility. An anesthetized VGE rabbit model examined respiratory breath-to-breath N 2 washout with gas mass spectroscopy (16) . Although there was a higher peak and a shorter time to baseline (plateau or near-zero N 2 ), the differences were not large or satisfying. If solubility of N 2 in PFC (10-to 50-fold) alone was the cause of the enhanced survival, as seen in the swine studies, then breath-to-breath washout did not demonstrate enough of a difference to account for the 65% improvement in survival. Studies were undertaken in highly instrumented animals to understand the effects of PFC on not only N 2 off-gassing but O 2 supply, utilization, cardiac output, pulmonary function, etc. These studies are presented in this issue (60a). It was found that Oxycyte (Synthetic Blood International, now Oxygen Biotherapeutics, Costa Mesa, CA), a third-generation 60% emulsion PFC, increases total O 2 content, O 2 delivery, and respiratory N 2 washout (N 2 plateau). It is important to note that, even though the respiratory N 2 had plateaued at an asymptote to zero, there was considerable cardiopulmonary, intravascular bubble formation present, with or without PFC. Survival in swine, sheep, and small animals tested with IV PFC in the face of DCS appears to be caused by all aspects of PFC-enhanced gas delivery and removal. Both enhanced tissue O 2 supply, through diffusivity, microparticle low-flow delivery, and some element of N 2 off loading combined.
In other studies of bubble generation/dissolution, PFC has been shown to improve both. Using a Russian manufactured first-generation PFC Perftoran (Perfluorodecalin, 10% vol/vol) in a rat cremaster microcirculation preparation, the speed of bubble resolution was increased by 36% (79) . PFC presence made bubbles smaller and had them move further distal into the smaller diameter vasculature. Bubble dissolution was most effective when PFC was a pretreatment, before bubble delivery. The pretreatment with PFC also allowed for enhanced numbers of stick/slippage events per bubble. Normally, an AGE bubble lodges and sticks to arteriolar small-vessel endothelial cells. Eckmann and Armstead (15) have demonstrated that bubble surfaces stimulate endothelial cells to release adherent molecules. PFC micelles not only shrunk the bubbles, but caused them to slip, slide, and move. This observation means that PFC may act through surfactant actions. Bubbles create shear stress, vascular stretch, and even massive heat as they shrink (15) . The outside of the PFC micelle is itself a surfactant, but the PFC, being inert and unable to form bonds to any biological compound, may well have unique interactions here as well as on the shear stress. Herren et al. (27, 28) found similar endothelial bubble effects during CPB in the retina of swine. Through retinal angiograms and matched vascular perfusion (horseradish peroxidase) stained flat mounts, they were able to demonstrate that vessels that had been involved with air emboli later developed microvascular endothelial dysfunctionfluid leakage (Fig. 4) (27, 28) . PFC prevented endothelial leakage. Others have noted that PFC infused into the CPB pump decreases white cell activation normally seen with heart surgery (19) . It could well be that the decrease in air emboli, leading to or coupled with decreased endothelial cell activation, may be responsible for the decreased white cell activation.
Other explanations of white cell suppression have been examined extensively. In a rat model of CPB, a bubble-dissolving study was undertaken (78) . A room air bubble was introduced into the reservoir of the CPB machine. The reservoir had different gases bubbled through it, as well as different fluids added as either a control or experimental (Oxycyte) grouping. The Oxycyte-treated group had a 13% decrease in bubble size over 20 min (78) . One should note that the gases used in the CPB machine were 60% O 2 , 36% N 2 , and 4% CO 2 ; so there was still N 2 present.
Returning to our work, with different inhaled gases in the anesthetized sheep model of DCS, we were able to show that He-O 2 breathing does increase the speed of N 2 off-gassing out of the trachea (60a). Gas diffusion gradients appear to be the key to much success using PFC (Henry's Law). In severe cardiopulmonary DCS studies, heterogeneity of DCS generation and large differences in severity of pathophysiological consequences are the rule. By retinal angiography coordinated in our DCS studies, we have noted only about a 20 -30% incidence of retinal AGE. The presence of AGE is not specifically related to a patent foramen ovale (necropsy examination). Some have suggested that pulmonary off-gassing across the alveolar membrane may well be the final and most important obstacle for getting N 2 out of the body. The alveolar membrane is aqueous and, therefore, relatively impermeable to N 2 , O 2 , and other respiratory gasses. This review has already discussed the importance of enhanced solubility for respiratory gas movements and the resistance to those movements created by water-based fluids. Movement of O 2 is impeded by plasma resistance. Cell cytosol is water based, and movement across alveolar cells may well be a resistance to N 2 exiting the body. The alveolar gas space, of course, develops an equilibrium of N 2 , even if 100% O 2 is inspired. The N 2 flow may be impeded to some extent by the water-based cytosol of the alveolar lining cells. It is an evolutionary advantage that the alveolar membrane (conceptually a bubble surface itself) separating outside air from intravascular circulation is so very thin. It only works when surfactant is present. The surfactant stabilizes the alveolar size and surface tension. But surfactant (if made nonpolar) may also enhance nonpolar gas movements (as yet to be studied). Most of the work discussed so far has been utilizing IV liquid PFC emulsions made into micelles. A novel technique has found similar results in terms of improved N 2 removal using PFC microbubbles. Volatile PFC has been utilized as an echocardiographic and magnetic resonance contrast agent. Dodeca-perfluoropentane (NuV Pharma, Tucson, AZ) has a boiling point (phase change to gas) of 22-28°C, meaning that, when a microparticle of it is injected, it will flash and vaporize into a pure PFC microbubble. This particle has been shown to improve tissue O 2 delivery. Bubble dissolution has been improved up to 33% by the use of dodeca-perfluoropentane IV as well (42) .
CONCLUSIONS
The focus of this review has been to discuss the mechanisms by which PFC changes all nonpolar gas movements. Understanding these physical chemical forces with respect to PFC will allow the proper medical applications of these emulsions. Today, PFC applications cannot be viewed only as a "blood substitute," but as enhancers of all respiratory gas movements. In summary, gas solubility/shortened diffusion distance (micelle to micelle) in plasma is enhanced by the presence of PFC emulsions/microparticles. PFC carries respiratory gases in equilibrium with partial pressures of the gases based on Henry's Law. All gases are affected, not just O 2 . O 2 movement from Hb to tissues is inhibited by its water solubility (plasma), and, in that way, all gas movements are analogous. Hb carries a large reservoir of O 2 . The enhanced tissue delivery of O 2 by PFC is an advantage, but it should be viewed as a demonstration for how other gases could move as well. PFC can enhance N 2 off (on) loading. It can also enhance argon, xenon, helium, NO, and gas flows between tissues and blood as well. The work discussed regarding treatment/prevention of AGE, VGE, and DCS shows that, with proper understanding of gas solubility, PFC can creatively be utilized. The fundamental understanding of gas flows is what will lead to the advantageous use of these agents.
FUTURE WORK
Today work has just begun on understanding these effects. Much work remains. For example, IV PFC increases cerebral blood flow. We do know that PFC increases CO 2 solubility compared with plasma solubility, the greatest of all respiratory gas. But what is the mechanism responsible for the enhanced cerebral blood flow? Are we so sure it is due to CO 2 fluxes? We do not know if an enhanced flow of CO 2 is a benefit or detraction in normal and disease states. We certainly do not know whether CO 2 flux is different in different tissues. Data from animal and human work have shown dramatically improved cerebral O 2 delivery in the face of TBI (Fig. 5) . Is the observed brain tissue salvage in TBI dependent on early O 2 delivery to neurons at risk because of enhanced diffusivity or total cerebral blood flow enhancement? Studies are underway to examine brain salvage after both civilian trauma (blunt) and military (blast) TBI with PFC (Oxycyte). Similar work has just been published demonstrating increased O 2 delivery to the spinal cord after trauma (59) . Although biocomputational modeling has progressed, future work needs to be performed in the microcirculation to confirm or deny these models. The limits of PFCs' capabilities to deliver O 2 to tissues with low blood flow
is not yet known. That one fundamental piece of information would further enhance the appropriate use of these compounds. Is there something about gas movement in vessel-rich tissues like brain and spinal cord that is uniquely important and positively affected by PFC? Clearly we have gained a great deal of knowledge regarding PFC and shown promise in DCS, gas embolism, and N 2 diffusion. Only one study has examined NO movement with PFC (54) . NO is so vital to blood flow regulation, inflammation, platelet adhesion, and other processes that we need a great deal of research in NO and the microcirculation with and without PFC. It has even been suggested that PFCs could be utilized in new NO delivery technology (54) . An understanding of how each gas moves to and from tissues in the presence of PFC, especially in the face of various disease states, is vital. Once these questions are more fully answered, then we can use that information constructively so that the revolution in medicine can be fully actualized.
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